Ratings by Leerink (Joseph P. Schwartz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Outperform (N/A) |
0.97 (0.97) |
0% | Details | |
| 6/2/2026 | Fulcrum Therapeutics | FULC | Downgrade | Market Perform (Outperform) |
6.42 (3.93) |
-38.79% | Details | |
| 3/31/2026 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2026 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2025 | Applied Therapeutics | APLT | Downgrade | Market Perform (Outperform) |
0.21 (0.10) |
-52.38% | Details | |
| 12/3/2025 | Inflarx NV | IFRX | Downgrade | Market Perform (Outperform) |
0.99 (2.00) |
102.02% | Details | |
| 11/18/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2025 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2025 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2025 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2025 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2025 | PTC Therapeutics | PTCT | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/7/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2025 | Fulcrum Therapeutics | FULC | Upgrade | Outperform (Market Perform) |
6.12 (6.42) |
4.9% | Details | |
| 5/5/2025 | PTC Therapeutics | PTCT | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/17/2025 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2024 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2024 | Applied Therapeutics | APLT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2024 | Fulcrum Therapeutics | FULC | Downgrade | Market Perform (Outperform) |
8.85 (3.93) |
-55.59% | Details | |
| 2/22/2024 | Applied Therapeutics | APLT | New Coverage | Outperform (N/A) |
5.13 (0.21) |
-95.91% | Details | |
| 12/19/2023 | WAVE Life Sciences | WVE | Upgrade | Outperform (Market Perform) |
4.49 (6.10) |
35.86% | Details | |
| 12/15/2023 | Reneo Pharmaceuticals | RPHM | Downgrade | Market Perform (Outperform) |
7.75 (1.82) |
-76.52% | Details | |
| 8/18/2023 | Selecta Biosciences | SELB | Downgrade | Market Perform (Outperform) |
1.12 (0.88) |
-21.43% | Details | |
| 6/12/2023 | Reata Pharmaceuticals | RETA | Upgrade | Outperform (Market Perform) |
93.80 (172.36) |
83.75% | Details | |
| 3/17/2023 | PTC Therapeutics | PTCT | New Coverage | Market Perform (N/A) |
48.10 (84.15) |
74.95% | Details | |
| 12/13/2022 | Horizon Therapeutics | HZNP | Downgrade | Market Perform (Outperform) |
112.36 (116.30) |
3.51% | Details | |
| 10/20/2022 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | Horizon Therapeutics | HZNP | Upgrade | Outperform (Market Perform) |
66.96 (116.30) |
73.69% | Details | |
| 6/6/2022 | Merck | MRK | New Coverage | Outperform (N/A) |
89.91 (120.03) |
33.5% | Details | |
| 6/6/2022 | Horizon Therapeutics | HZNP | New Coverage | Market Perform (N/A) |
91.29 (116.30) |
27.4% | Details | |
| 6/6/2022 | Selecta Biosciences | SELB | New Coverage | Outperform (N/A) |
0.88 (0.88) |
0% | Details | |
| 5/31/2022 | PepGen Inc. | PEPG | New Coverage | Outperform (N/A) |
10.88 (1.84) |
-83.09% | Details | |
| 5/9/2022 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2021 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2021 | Reata Pharmaceuticals | RETA | Downgrade | Market Perform (Outperform) |
54.42 (172.36) |
216.72% | Details | |
| 11/5/2021 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2021 | Travere Therapeutics | TVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2021 | Reneo Pharmaceuticals | RPHM | New Coverage | Outperform (N/A) |
14.50 (1.82) |
-87.45% | Details | |
| 10/26/2020 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2019 | Reata Pharmaceuticals | RETA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2018 | Spark Therapeutics | ONCE | Maintain | Market Perform (N/A) |
|
Details |
